Triumeq Approval History
Triumeq (abacavir, dolutegravir and lamivudine) is a fixed-dose combination containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine for the treatment of HIV-1 infection.
Development History and FDA Approval Process for Triumeq
|Aug 22, 2014||FDA Approves Triumeq for the Treatment of HIV-1 Infection|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.